Fidson Healthcare Seeks N30 Billion Capital Raise as Share Price Surges 183 Percent

Strategic Insights -

Fidson Healthcare, a Nigerian pharmaceutical company, is seeking to raise an additional N30 billion through equity financing at its upcoming annual meeting of shareholders. The company's share price has seen an impressive 183 percent increase this year, driven by a boom in prescription medicine sales. Fidson's collaboration with Serum Institute of India Pvt Limited led to the production of Nigeria's first malaria vaccine in 2023, which has been touted as a potential solution to malaria-induced mortality in tropical Africa. The company is also expanding its operations through partnerships with Asian companies, including a joint venture deal with China-Africa Development Fund to establish a pharmaceutical plant in Nigeria.

Key Takeaways:

  • Fidson Healthcare is seeking to raise an additional N30 billion through equity financing at its upcoming annual meeting of shareholders.
  • The company's share price has increased by 183 percent this year, driven by a boom in prescription medicine sales.
  • Fidson has a breakthrough collaboration with Serum Institute of India Pvt Limited to produce Nigeria's first malaria vaccine in 2023.
  • The company is expanding its operations through partnerships with Asian companies, including a joint venture deal with China-Africa Development Fund to establish a pharmaceutical plant in Nigeria.
  • The plant, located in the Lekki Free Trade Zone, will cater to the needs of 1.9 million HIV patients in Nigeria.
  • Fidson's net profit for the first quarter of this year more than tripled to N3.3 billion.
  • The company's assets totalled N80.5 billion at the end of March, compared to N73.5 billion last December.
  • Fidson is expected to distribute N2.3 billion in total dividends to shareholders at N1 per share for the financial year 2024.

Statistics:

  • 183 percent increase in Fidson's share price this year.
  • N3.3 billion as the company's net profit for the first quarter of this year.
  • N80.5 billion as the company's total assets at the end of March.
  • N73.5 billion as the company's total assets last December.
  • N2.3 billion as the total dividends to be distributed to shareholders for the financial year 2024.
  • 1.9 million as the number of HIV patients in Nigeria to be catered to by Fidson's pharmaceutical plant.

Sources:

  • "Fidson Pharmaceuticals (FIDSONHOLD) – Regulatory Announcement" by Fidson Healthcare.
  • "Fidson Pharmaceuticals, China-Africa Development Fund, Jiangsu Aidea Pharma and Nanjing PharmaBlock close JV deal" by Premium Times.
  • "Fidson Healthcare records N3.3 billion profit in Q1 2024" by Premium Times.
  • "Fidson Healthcare to distribute N2.3 billion dividend" by Premium Times.